Addiction, Behavior, Brain, Depression, Epigenetics, Gene Therapy, Knockout Mice, Membrane Proteins/Channels, Molecular Biology, Neurobiology, Neuroscience, Obesity, Protein Complexes, Signal Transduction, Spinal Cord, Synaptic Plasticity, Systems Neuroscience, Tolerance, Transcription Factors, Transgenic Mice
Biophysics and Systems Pharmacology [BSP], Neuroscience [NEU]
EnglishDownload the CV
Mitsi V, Terzi D, Purushothaman I, Manouras L, Gaspari S, Neve RL, Stratinaki M, Feng J, Shen L, Zachariou V. RGS9-2--controlled adaptations in the striatum determine the onset of action and efficacy of antidepressants in neuropathic pain states. Proceedings of the National Academy of Sciences of the United States of America 2015 Sep; 112(36).
Descalzi G, Ikegami D, Ushijima T, Nestler EJ, Zachariou V, Narita M. Epigenetic mechanisms of chronic pain. Trends in neurosciences 2015 Apr; 38(4).
Caldarone BJ, Zachariou V, King SL, Nestler EJ, Zachariou V, Narita M. Rodent models of treatment-resistant depression. European journal of pharmacology 2014 Nov;.
Terzi D, Gaspari S, Manouras L. RGS9-2 modulates sensory and mood related symptoms of neuropathic pain. Neurobiology of learning and memory 2014 Nov; 115.
Stratinaki M, Varidaki A, Mitsi V, Ghose S, Magida J, Dias C, Russo SJ, Vialou V, Caldarone BJ, Tamminga CA, Nestler EJ, Zachariou V. Regulator of G protein signaling 4 is a crucial modulator of antidepressant drug action in depression and neuropathic pain models. Proceedings of the National Academy of Sciences of the United States of America 2013 May; 110(20).
Gaspari S, Papachatzaki MM. Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2014 Jul; 39(8).
Psifogeorgou K, Terzi D, Papachatzaki MM, Varidaki A, Ferguson D, Gold SJ, Zachariou V. A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia. The Journal of neuroscience : the official journal of the Society for Neuroscience 2011 Apr; 31(15): 5617-24.
Terzi D, Cao Y, Agrimaki I, Martemyanov KA, Zachariou V, Risch SC, Fairbrother WG, Neve RL, Kane JP, Malloy MJ, Pullinger CR, Mitsi D, Tsatsanis C, Hamilton SP, Gold SJ, Zachariou V, Kovoor A. R7BP modulates opiate analgesia and tolerance but not withdrawal. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2012 Mar; 37(4): 1005-12.
Han MH, Renthal W, Ring RH, Rahman Z, Psifogeorgou K, Howland D, Birnbaum S, Young K, Neve R, Nestler EJ, Zachariou V, Gu HF, Tsatsanis C, Hamilton SP, Gold SJ, Zachariou V, Kovoor A. Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia. Biological psychiatry 2010 Apr; 67(8): 761-9.
Traynor JR, Terzi D, Caldarone BJ, Zachariou V, Psifogeorgou K, Howland D, Birnbaum S, Young K, Neve R, Nestler EJ, Zachariou V. RGS9-2: probing an intracellular modulator of behavior as a drug target. Trends in pharmacological sciences 2009 Mar; 30(3): 105-11.
Krishnan V, Graham A, Mazei-Robison MS, Lagace DC, Kim KS, Birnbaum S, Eisch AJ. Calcium-sensitive adenylyl cyclases in depression and anxiety: behavioral and biochemical consequences of isoform targeting. Biological psychiatry 2008 Aug; 64(4): 336-43.
Charlton JJ, Allen PB, Psifogeorgou K. Multiple actions of spinophilin regulate mu opioid receptor function. Neuron 2008 Apr; 58(2): 238-47.
McClung CA, Nestler EJ, Zachariou V, Rahman Z, DiLeone R, Berton O, Neve RL, Sim-Selley LJ, Selley DE, Gold SJ, Nestler EJ. Regulation of gene expression by chronic morphine and morphine withdrawal in the locus ceruleus and ventral tegmental area. The Journal of neuroscience : the official journal of the Society for Neuroscience 2005 Jun; 25(25): 205-11.
Zachariou V, Georgescu D, Sanchez N, Rahman Z, DiLeone R, Berton O, Neve RL, Sim-Selley LJ, Selley DE, Gold SJ, Nestler EJ. Essential role for RGS9 in opiate action. Proceedings of the National Academy of Sciences of the United States of America 2003 Nov; 100(23): 6005-15.
Carr FB, Zachariou V, Manouras L, Descalzi G, Mitsi V, Zachariou V. Nociception and pain: lessons from optogenetics. Frontiers in behavioral neuroscience 2014; 8.
Stergiou E, L SL, Zachariou VL, Psifogeorgou K, Howland D, Birnbaum S, Young K, Neve R, Nestler EJ, Zachariou V. . Progress in molecular biology and translational science;: Zachariou.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Zachariou has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.